Shabana Ather

536 total citations
12 papers, 401 citations indexed

About

Shabana Ather is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Shabana Ather has authored 12 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Epidemiology. Recurrent topics in Shabana Ather's work include Bone health and treatments (5 papers), Bone health and osteoporosis research (4 papers) and Bone Metabolism and Diseases (4 papers). Shabana Ather is often cited by papers focused on Bone health and treatments (5 papers), Bone health and osteoporosis research (4 papers) and Bone Metabolism and Diseases (4 papers). Shabana Ather collaborates with scholars based in United States, Canada and France. Shabana Ather's co-authors include Dimitris A. Papanicolaou, B. B. Scott, Julie Chandler, Hao Zhu, Yuedan Zhou, Thomas Fuerst, Bernard J. Dardzinski, Klaus Engelke, Anne E. de Papp and Nadia Verbruggen and has published in prestigious journals such as Gastroenterology, The Journal of Clinical Endocrinology & Metabolism and Journal of Bone and Mineral Research.

In The Last Decade

Shabana Ather

11 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shabana Ather United States	6	204	139	126	96	49	12	401
Gillian Wheater United Kingdom	5	121 0.6×	167 1.2×	86 0.7×	36 0.4×	24 0.5×	8	360
David Myles United States	4	217 1.1×	32 0.2×	72 0.6×	27 0.3×	24 0.5×	6	299
Shanhua Mao China	12	260 1.3×	29 0.2×	57 0.5×	17 0.2×	26 0.5×	34	557
G. Alonso Argentina	11	264 1.3×	27 0.2×	176 1.4×	32 0.3×	15 0.3×	42	535
Rossella Belleli Switzerland	9	97 0.5×	130 0.9×	156 1.2×	22 0.2×	13 0.3×	16	440
Dihua Zhang China	8	100 0.5×	57 0.4×	25 0.2×	40 0.4×	21 0.4×	16	348
Zheran Liu China	12	110 0.5×	12 0.1×	110 0.9×	58 0.6×	17 0.3×	68	504
Philip Stein United States	10	89 0.4×	11 0.1×	87 0.7×	191 2.0×	29 0.6×	12	411
Gilberto Uemura Brazil	10	92 0.5×	21 0.2×	230 1.8×	34 0.4×	53 1.1×	31	474
Usha Sriram India	8	150 0.7×	194 1.4×	170 1.3×	15 0.2×	166 3.4×	13	435

Countries citing papers authored by Shabana Ather

Since Specialization

Citations

This map shows the geographic impact of Shabana Ather's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shabana Ather with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shabana Ather more than expected).

Fields of papers citing papers by Shabana Ather

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shabana Ather. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shabana Ather. The network helps show where Shabana Ather may publish in the future.

Co-authorship network of co-authors of Shabana Ather

This figure shows the co-authorship network connecting the top 25 collaborators of Shabana Ather. A scholar is included among the top collaborators of Shabana Ather based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shabana Ather. Shabana Ather is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Ungaro, Ryan C., Corey A. Siegel, Bruce Cree, et al.. (2022). P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials. Journal of Crohn s and Colitis. 16(Supplement_1). i452–i452. 1 indexed citations

Rubin, David T., Freddy Caldera, Jeffrey Cohen, et al.. (2022). S812 Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials. The American Journal of Gastroenterology. 117(10S). e581–e581.

Reinisch, Walter, Jordan E. Axelrad, Shabana Ather, et al.. (2022). P431 Early mucosal healing at week, 10 with ozanimod predicts clinical outcomes at week, 52: Post hoc analysis of the phase, 3 True North clinical trial. Journal of Crohn s and Colitis. 16(Supplement_1). i415–i415. 2 indexed citations

D’Haens, Geert, Jean‐Frédéric Colombel, Gary R. Lichtenstein, et al.. (2021). 128 SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS. Gastroenterology. 160(6). S–35. 1 indexed citations

Sands, Bruce E., Brian G. Feagan, William J. Sandborn, et al.. (2019). Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. The American Journal of Gastroenterology. 115(5). 738–745. 64 indexed citations

Langdahl, Bente, Tony M. Keaveny, Klaus Engelke, et al.. (2016). Effect of odanacatib on bone density and estimated bone strength in postmenopausal women: a CT-based sub-study of the phase 3 long-term odanacatib fracture trial (LOFT). Bone Abstracts. 3 indexed citations

Engelke, Klaus, Thomas Fuerst, Bernard J. Dardzinski, et al.. (2014). Odanacatib Treatment Affects Trabecular and Cortical Bone in the Femur of Postmenopausal Women: Results of a Two-Year Placebo-Controlled Trial. Journal of Bone and Mineral Research. 30(1). 30–38. 34 indexed citations

Cheung, Angela M., Sharmila Majumdar, Kim Brixen, et al.. (2014). Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture, and Estimated Bone Strength. Journal of Bone and Mineral Research. 29(8). 1786–1794. 53 indexed citations

Brixen, Kim, Roland Chapurlat, Angela M. Cheung, et al.. (2013). Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial. The Journal of Clinical Endocrinology & Metabolism. 98(2). 571–580. 95 indexed citations

10.

Papanicolaou, Dimitris A., Shabana Ather, Hao Zhu, et al.. (2013). A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. The journal of nutrition health & aging. 17(6). 533–543. 132 indexed citations

11.

Wynne, Christopher, Anders Bonde Jensen, Steinar Lundgren, et al.. (2008). OC2. Efficacy, pharmacokinetics, and safety of a cathepsin K (Cat K) inhibitor in the suppression of bone resorption in women with breast cancer and established bone 2. Cancer Treatment Reviews. 34. 49–50. 1 indexed citations

12.

Ather, Shabana, et al.. (2004). The Association Between Hospital Readmission and Insurance Provider Among Adults with Asthma. Journal of Asthma. 41(7). 709–713. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact